KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

Recruiting

Phase 3

SonlicromanolKHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

Sponsor:

Khondrion BV

Code:

NCT06451757

Conditions

Mitochondrial Diseases

Maternally Inherited Diabetes and Deafness (MIDD)

Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)

Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sonlicromanol

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-10. This information was provided to ClinicalTrials.gov by Khondrion BV on 2026-06-29.